Horizon Therapeutics Plc Overview
Horizon Therapeutics Plc (HZNP) has a P/E ratio of 51.01, above the Healthcare sector average of 26.85.
Get informed when a big investor buys or sells
+ Follow51.01
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, HZNP shows a P/E ratio of 51.01. That is above the Healthcare sector average of 26.85. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 26.85. Horizon Therapeutics Plc is at 51.01, which is higher that average. That is roughly 90.0% above the sector mean. Use the comparison chart on this page to see how HZNP stacks up against individual peers as well.
Investors watch HZNP's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Horizon Therapeutics Plc's latest reading is 51.01. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has Horizon Therapeutics Plc's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently 51.01) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 26.85, while HZNP is at 51.01. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
